Abstract Treating the pregnant woman poses challenges to the physician that requires balancing between eliminating or alleviating a condition or disease and ensuring no untoward effects on the mother and fetus. Despite the importance of the task, human studies are limited for obvious reasons, and animal studies do not fully resemble human physiology. Nevertheless, thanks to epidemiology studies and large-scale reviews of case reports on pregnant patients with comorbidities or refractory diseases that necessitate treatment with drugs of uncertain safety, data are accumulating on the safety of medications during pregnancy. This review summarizes the current literature on the safety during pregnancy of medications frequently used for common dermatologic diseases. The goal is to provide physicians with a handy database for when to, and when not to, prescribe those medications.
Introduction
One of the challenges physicians and dermatologists face is treating women with dermatologic conditions or diseases who are pregnant, planning to become pregnant, or sexually active and not using contraceptives. Teratogenic medications must be avoided in all of them. This review summarizes the current literature on the safety during (and before) pregnancy of medications frequently prescribed for common dermatologic diseases. The goal is to provide dermatologists and physicians with a handy database to consult when confronted with such a patient. The data are based on a literature survey of animal studies and human cases. This article does not contain any studies with human or animal subjects performed by any of the authors.
Safety Categories of Medications During Pregnancy
The U.S. Food and Drug Administration (FDA) pregnancy and lactation categories are commonly referred to for the safety of medications during pregnancy (Tables 1 and 2 ). These categories do not cover breastfeeding risk. Because experimental medications cannot be tested on pregnant women, the categories are based on animal studies and epidemiologic data. According to the FDA chart: categories A and B are safe during pregnancy, C should be given only if the potential benefit justifies the potential risk to the fetus, and D should be given only in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective. Drugs from category X should be avoided in pregnant women, because the risks outweigh any possible benefit [1] .
Corticosteroids
Topical corticosteroids are used as first-line treatment for a wide range of dermatoses, including psoriasis, atopic dermatitis, allergies, and polymorphic eruption of pregnancy (PEP) [2•] . Although listed in category C, the literature indicates that they are first-line therapy in inflammatory diseases during pregnancy [3] . Several studies of infants whose mothers were treated with topical corticosteroids during pregnancy found no increased risk of low birth weight, congenital anomalies, or preterm delivery [4] . However, there are case reports of low birth weight after large amounts of topical corticosteroid therapy [3] . Some studies reported a higher prevalence of cleft lip and palate when topical corticosteroids were used during pregnancy, whereas other studies found no such association [5, 6] .
Systemic corticosteroids are not commonly used during pregnancy, except for bullous diseases, severe allergies, and specific dermatoses of pregnancy, such as pemphigoid gestationis [2•] . High-dose oral corticosteroid therapy during pregnancy was associated with intrauterine growth retardation, low birth weight infants, and inhibition of endogenous corticosteroid production, and several studies have documented a higher prevalence of orofacial clefts, although other studies found no such association [5, 6] .
Anti-Fungal Agents
There is a higher prevalence of certain fungal infections during pregnancy, such as candida vaginitis, and a higher risk of a more virulent course for infections, such as coccidioidomycosis [7] .
Azoles
Ketoconazole is indicated as topical treatment for superficial fungal infections, such as tinea pedis, due to dermatophytes. The drug was associated with teratogenic risk in animal studies when administered orally, and it is category C. Systemic ketoconazole was associated with androgen synthesis inhibition, increased risk of sexual ambiguity of male fetus, progesterone secretion impairment, and interference with early pregnancy and implantation; it should not be used during pregnancy. However, because the topical absorption is minimal, ketoconazole is generally considered safe as topical treatment [7] .
Clotrimazole and Mycostatin are used topically against local fungal infections due to candida, such as oral thrush or vaginal candidiasis. Both are category B and safe during pregnancy [7] . Itraconazole and fluconazole were associated with congenital malformations. Both are category C and should not be given during pregnancy [7] .
Other Antifungal Agents
Terbinafine is commonly indicated as a systemic treatment for onychomycosis. It is category B, considered safe during pregnancy, and the treatment of choice for dermatophyte infection during pregnancy. However, the manufacturer recommends delaying the treatment of onychomycosis with oral terbinafine until after delivery [7] .
Griseofulvin was associated with skeletal and central nerve system anomalies and fetal loss in animal studies. It is category C and should not be used during pregnancy [7] .
Selenium sulfide is indicated for tinea versicolor. In animal studies, oral selenium sulfide was associated with carcinogenic risk, but when administered topically, there was no such association. It is category C [8] .
Antibiotics

Miscellaneous Topical Antibiotics
Mupirocin is indicated as a topical treatment of localized bacterial infection, such as impetigo, folliculitis, and nose or perianal staphylococcal carriage. It is category B and is recommended for use during pregnancy [9] .
Other topical treatments for impetigo and folliculitis are fusidic acid, gentamicin, and bacitracin. Data on their effect on pregnancy is meager, and they are classified as category C. There are, however, several reports on the use of topical fusidic acid and systemic gentamicin during pregnancy, with no untoward effects [10, 11] .
Beta Lactamases
Penicillin is the treatment of choice for erysipelas and syphilis [12•, 13] . It is category B and is considered safe during pregnancy. When treating syphilis, it is important to keep in mind the Jarisch-Herxheimer reaction, which may appear 4-6 hours after initiation of the treatment. It is caused by release of treponemic antigens to the blood and is characterized by fever, headache, chills, and muscle pain. In pregnant patients, it may cause fetal death [12•] . Other beta lactamase antibiotics, such as cephalexin, cefazolin, cloxacillin, and amoxicillin/clavulanic acid, which are used to treat cellulitis, are all category B and safe during pregnancy [1] .
Cephalosporins
Ceftriaxone is the first-line treatment for gonococcal urethritis. It is category B and safe during pregnancy [12•] . 
Lincosamides
Clindamycin is a safe, category B, topical treatment for acne during pregnancy and an alternative safe systemic treatment for pregnant patients with cellulitis who are allergic to penicillin [12•] .
Fluoroquinolones
Ciprofloxacin is suggested as a part of empiric antibiotic regimen therapy for moderate to severe infected diabetic foot [14] . It is category C, but a number of reviews and studies found no increased risk of preterm delivery, spontaneous abortion, or major malformations with the drug, and the authors considered it safe during pregnancy [15] [16] [17] . An optional treatment for nongonococcal urethritis is ofloxacin [12•] , but because it is category C, it is better to use macrolides (discussed below) for this condition during pregnancy.
Macrolides
Erythromycin, category B, is an alternative treatment for nongonococcal urethritis in pregnant women and for treating syphilis in pregnant women sensitive to penicillin [12•] . It may cure the mother of syphilis but not the infant. If the mother is an HIV carrier, the physician should be aware of [18] . Because it is a category B drug, erythromycin is considered safe during pregnancy, although some studies found an association between use of erythromycin early in pregnancy and cardiovascular malformations, and between prolonged use of erythromycin ethylsuccinate formulation and hepatotoxicity [12•] . Other studies found no such associations [19] . An alternative macrolide for later pregnancy is azithromycin, which also is category B and considered safe during pregnancy [12•, 20] .
Clarithromycin, a category C drug, is indicated as a systemic treatment for skin infections due to atypical mycobacteria [21] . Recent animal studies and reviews of pregnant human patients who were treated with clarithromycin did not turn up a higher risk of congenital anomalies and malformations [16, 19] . Other studies, however, have documented a higher risk of miscarriage in patients treated with clarithromycin during early pregnancy [21] .
Tetracyclines Doxycycline, which is indicated for treatment of nongonococcal urethritis and Q fever, and minocycline, which is indicated for treatment of acne and rosacea, are category D and should not be used during pregnancy. Tetracyclines are associated with enamel hypoplasia and yellowish staining of the teeth in the second and third trimesters, and acute fatty liver of pregnancy in the third trimester. They were not associated with congenital anomalies when given in the first trimester [20] .
Anti-Viral Agents
Acyclovir is indicated as a topical treatment for herpes simplex or as a systemic treatment for herpes zoster, genital herpes, or varicella. Acyclovir is extremely important as a treatment for seronegative pregnant patients who are infected with varicella, in order to lower the risk of congenital varicella syndrome [22] . It is category B and safe during pregnancy [12•, 23, 24] .
Topical fluorouracil and imiquimod are indicated for treatment of viral warts. They are classified as category X and C, respectively, and should not be used during pregnancy. It is recommended to use physical methods to treat verruca, such as cryotherapy, during pregnancy [12•] .
Antiparasitic Agents
The treatment of choice indicated for pregnant patients suffering from scabies is topical permethrin, which is category B and safe during pregnancy [22, 25] . Ivermectin is an off-label treatment for Norwegian scabies. Several studies included pregnant patients treated with ivermectin, but data are insufficient to determine its safety [26] . Ivermectin is currently a category C drug and should not be used during pregnancy.
A formulation of paromomycin and methylbenzethonium chloride is a topical treatment indicated for cutaneous leishmaniasis. Data on its safety during pregnancy are inadequate, and it is not categorized [27] .
Sodium stibogluconate is indicated as a treatment for leishmaniasis. Studies have included pregnant patients treated with the drug, but data are insufficient to determine its safety [28] .
Liposomal amphotericin B is a broad spectrum antifungal, which is used in dermatology as a safe (category B) treatment for visceral leishmaniasis during pregnancy [7, 29, 30] . Although it crosses the placenta, animal studies did not demonstrate a teratogenic risk, and there are no reports of congenital anomalies in infants whose mothers were exposed to amphotericin B during pregnancy. The disadvantages of the drug are its side effects, which include nephrotoxicity and hypokalemia [7] .
Immunosuppressants
Methotrexate, which is indicated for treatment of psoriasis, is category X and should not be used in pregnant women. Methotrexate is associated with an increased risk of miscarriage, micrognathia, developmental delays, craniosynostosis, small low-set ears, limb abnormalities, prenatal growth retardation, and mental retardation [3] .
Pimecrolimus and tacrolimus, which are used topically to treat atopic dermatitis, are category C. There were reports of congenital anomalies, neonatal hyperkalemia, low birth weight, and premature delivery when pimecrolimus was given orally, but the complex medical background of the patients made the association unclear. There are no reports on women treated with topical pimecrolimus during pregnancy, but because the absorption of the medication is low, the risk of teratogenic effect when used topically and sparingly is probably low [3, 31•] .
Cyclosporine is used in patients with severe psoriasis, especially the pustular and erythrodermic types [2•] . There are more than 800 reports of pregnant women treated with cyclosporine after kidney transplant, most of which were not associated with a higher rate of congenital anomalies than the general population. Some studies reported an increased incidence of prematurity and intrauterine growth retardation, but because the patients were mainly women with serious medical problems, undergoing kidney transplantation and being treated with several medications, the role of cyclosporine could not be determined. Cyclosporine is category C and is given to pregnant women when the benefits outweigh the potential risks [6, 31•] . The toxicities of cyclosporine, hypertension and nephrotoxicity, could complicate pregnancy [3] .
Cyclophosphamide, a nitrogen mustard alkylating agent, is used as an adjuvant therapy for dermatoses, such as pemphigus vulgaris, that are refractory to other treatments. It inhibits cell division and is teratogenic in animals and humans. It is category D and should be considered only if the benefits outweigh the risks. Some reviews consider it safe after the second trimester of pregnancy [6, 31•, 32] .
Azathioprine, a purine analogue, is another adjuvant therapy. Some studies found an association between azathioprine and a higher risk of preterm deliveries, without a higher risk of congenital malformations [6] . It is classified as category D and should be considered only if the benefits outweigh the risks described [6, 31•, 33] .
Biologic Immune Modifiers
These are indicated for treatment of moderate-to-severe plaque type psoriasis that is refractory to phototherapy and systemic treatments, or when other treatments are contraindicated; 40-60% of the patients with chronic psoriasis improve during pregnancy, but 10-20% experience worsening of the disease during pregnancy [34] . Most of the studies covered in our literature search were based on women with rheumatologic or gastrointestinal diseases, who were treated with immune modifiers during pregnancy.
The following immune modifiers are category B, but data on their effects during pregnancy are limited and conflicting [3] . Most of the cited studies examined antitumor necrosis factor alpha (TNFα). Although there were reports of congenital malformations and higher abortion rate [35] for infants born to patients treated with anti TNFα during pregnancy, it is important to emphasize that no specific pattern of congenital malformations was found in these studies. In addition, most of the these patients had rheumatoid arthritis, which is associated with a higher risk of congenital anomalies or prematurity compared with the general population; some of the patients were treated with several teratogenic medications, such as methotrexate.
In general, pregnant patients with widespread psoriatic plaques should be treated with UVB (discussed below) or cyclosporine. When there are contraindications, side effects, or refractory disease, the physician should consider immune modifiers [34] . Current data suggest that the risk of congenital anomalies is relatively low, and the benefits may outweigh the risks for patients with severe disease refractory to other treatments [36•] .
Etanercept is an anti-TNFα. A safety interval ranging from 3 weeks to 2 months is recommended between the last etanercept given and conception [37] . There are several reports of congenital malformations in infants born to pregnant women who had been treated with etanercept during their pregnancy. Several authors conclude that current data are insufficient to determine etanercept"s safety, and it should be avoided during pregnancy [36•, 38] .
Infliximab is a chimeric anti-TNFα. A safety interval of 2 to 6 months is recommended between the last infliximab given and conception [37] . Some reviews report several congenital malformations and other complications in infants born to mothers treated with infliximab during pregnancy [36•] , whereas other studies found no such association [6] . One study reported a higher rate of lower birth weight and prematurity, but it was not higher than the infants of pregnant patients with rheumatoid arthritis or Crohn's disease who were not treated with infliximab during pregnancy [3] .
Transplacental transport of IgG antibodies increases during the second and third trimesters. According to a few studies, when infliximab was given during the third trimester, it was detected in the infant's blood [37, 39] . However, it did not predispose the infants to a higher risk of infections, with the exception of one report of disseminated mycobacterial infection in an infant whose mother was given infliximab during pregnancy and the infant received BCG vaccine at 3 months of age. If infliximab is administered to a pregnant patient, it should be given during the first 30 weeks of pregnancy and resumed after delivery. Vaccinations with live viruses should be postponed in these infants until they are at least 6 months old [34, 39] .
Adalimumab is an anti-TNFα. A safety interval ranging from 2 to 5 months is recommended between the last adalimumab given and conception [37] . One review reported congenital malformations and other complications after adalimumab treatment during pregnancy [36•] , whereas other studies reported no such association [6] .
Ustekinumab is a human monoclonal anti-interleukin (IL)-12 and IL-23 antibody. There was a single report of an abortion in a pregnant woman receiving the drug [40] . Despite the comorbidities in this patient that included heavy smoking and psoriasis, which are associated with a higher risk of abortions [41] , it is currently recommended to avoid ustekinumab during pregnancy and to avoid pregnancy for at least 15 weeks after treatment.
Antihistamines
Antihistamines are indicated for treatment of allergies and to alleviate pruritus, one of the major dermatologic symptoms during pregnancy. It may be caused by specific dermatoses of pregnancy, atopic dermatitis of pregnancy, and allergies. Approximately 20-30% of pregnant patients experience allergic reactions during pregnancy [42] .
Chlorpheniramine, a first-generation antihistamine, category B, did not demonstrate any teratogenic risk in women or animal studies. It is regarded as first-line antihistamine treatment for pregnant patients who do not get relief with topical medications [42] . It is recommended as a treatment for dermatoses of pregnancy, such as mild pemphigoid gestationis, during the first trimester [2•]. The major side effects include sedation and anticholinergic effects, such as dry mouth, blurred vision, constipation, and urinary retention, so patients are advised to drink more water during the treatment [42] .
There are insufficient data on two other first generation antihistamines, promethazine and dimethindene. Promethazine is category C, whereas dimethindene is not categorized at all.
Previous studies have suggested that loratadine, a secondgeneration antihistamine, was associated with an increased risk of hypospadiasis, but more recent studies have found no such association and it is categorized as B. Loratadine is recommended as a treatment for dermatoses of pregnancy, such as mild pemphigoid gestationis, after the first trimester or for polymorphic eruption of pregnancy, if symptoms are not alleviated by topical treatment [2•] . Like all second-generation antihistamines, loratadine does not enter the central nerve system and is not sedating but might cause photosensitivity, tachycardia, and prolonged QT interval [42] . Fexofenadine and desloratadine, two other second generation antihistamines, are classified as category C.
Retinoids
The topical retinoids, aretinoin and adapalene, are indicated mainly for the treatment of inflammatory acne and rosacea. Several studies have suggested that these retinoids are teratogenic during the first trimester. Both are category C and should not be used during pregnancy [18] .
Acitretin is systemic retinoid used to treat psoriasis. It is category X. The risk of fetal anomalies is 25 times higher than for the general population. It may cause microtia/anotia, micrognathia, cleft palate, conotruncal heart defects and aorticarch abnormalities, thymic defects, retinal or optic-nerve abnormalities, and central nervous system malformations. Normally, total elimination of acitretin and its metabolites from the body takes up to 2 months. However, with alcohol consumption during treatment, acitretin is metabolized to etretinate, which has a half life of up to 168 days, and the teratogenic effect may hold up to 3 years. So, female patients should be advised not to drink alcohol during and at least 2 months after discontinuation of acitretin therapy and to use at least two kinds of contraception for 3 years after discontinuation of the drug [3] .
Alitretinoin, category D, is a systemic retinoid indicated for chronic hand eczema. It is teratogenic and may cause fetal malformations [43] . Female patients in their child-bearing years are required to use at least two forms of contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after finishing treatment, and also are required to take monthly pregnancy tests [44] .
Isotretinoin is a systemic retinoid prescribed for treating acne. It is category X and should not be used during pregnancy. During the first trimester, it may cause fetal loss, and later use may cause malformations, such as microtia, stenosis of the external ear canal, cleft palate, hydrocephalus, and cardiac outflow tract defects. Female patients of child-bearing age who are sexually active should use two methods of birth control during and for 1 month after treatment [18] .
Phototherapy-Associated Medications
Anthralin is a topical therapy for psoriasis used in the Ingram method, which combines topical anthralin with ultraviolet wave length B (UVB) phototherapy. There are no data on the effects of anthralin on human or animal pregnancies, and no evidence of anthralin's systemic absorption [3] . It is not categorized by the FDA.
Coal tar is combined with ultra UVB phototherapy in the Goeckerman method for treatment of psoriasis. Animal studies demonstrated teratogenic effects of the substance [3] . The only report in humans is a case of lethal anomaly in an infant whose mother was treated with coal tar during her pregnancy. Thus, the effects on pregnancy are not clear. It is listed as category C, although risk of anomalies during pregnancy is considered to be small if used for a short period of time [3] .
Narrow band UVB is used alone or with coal tar or anthralin to treat miscellaneous dermopathies. It is the firstline treatment for patients with extensive moderate psoriasis. UVB does not penetrate the skin and therefore is safe during pregnancy [45•, 46] .
Psoralen increases skin reactivity to ultraviolet wavelength A (UVA) and can be administered orally (systemic PUVA), or topically (local PUVA), with UVA phototherapy. In turn, UVA enhances psoralen's ability to bond with DNA, which inhibits DNA synthesis and cell division and leads to cell injury and mutagenic effects in vitro.
Several studies on systemic PUVA during human pregnancy found no increased risk of congenital anomalies or malformations. There was, however, a higher rate of low birth weight, and animal studies reported an increased rate of fetal death, growth retardation, and congenital anomalies, making it a category D drug and not to be used during pregnancy [45•] .
When psoralen is administered topically on small body surface areas, there is no evidence of systemic levels. In a study on local PUVA for the treatment of palmoplantar psoriasis, after the patients washed the psoralen off their hands and feet the drug was not detected in the blood [3] .
Miscellaneous Medications
Hydroxychloroquine is an aminoquinoline, antimalaria medication used for dermopathies, such as discoid lupus erythematosus. Although it is category C, several reviews and studies found no association between hydroxychloroquine and increased risk of congenital defects, spontaneous abortions, fetal death, prematurity, or decreased numbers of live births in patients with autoimmune diseases and consider it a safe medication during pregnancy [20, 47] .
Salicylic acid is a nonsteroidal anti-inflammatory drug (NSAID), used as a keratolytic medication, especially for psoriatic plaques. In addition, it improves the penetration of other topical medications. There are no studies on the effects of salicylic acid on human pregnancy, but other salicylates have been associated with human birth anomalies. For example, aspirin was associated with an increased risk of gastroschisis, hemostasis, and low birth weight; diclofenac, another NSAID, was associated with constriction of the ductus arteriosus. Therefore, salicylic acid is considered category C. If prescribed during pregnancy, the patient should be advised to use it for only a short period of time on small areas, with no occlusive dressings [3] .
Calcipotriol is a synthetic vitamin D3 for treatment of local psoriasis. It can be used with betamethasone to lower its local irritation and increase its effectiveness. Animal studies demonstrated a higher risk of coronary anomalies and miscarriages when administered during pregnancy. Although it is suggested that local topical treatment would not increase teratogenic risk, there are no reports on humans, so it is classified as category C [3] .
Azelaic acid is indicated for treatment of acne. It is category B and considered safe during pregnancy [48] .
Ammonium bituminosulfonate (ichthammol) is produced from oil shell, an organic rich sedimentary rock. In the United States, it is approved only for veterinary use. Outside the United States, it is used as a "drawing salve" for a variety of inflammatory dermatoses, including psoriasis, leg ulcers, eczematous, and seborrheic dermatitis, with no evidence of a teratogenic risk [49, 50] .
Benzoyl peroxide is a topical substance for treatment of acne. It reduces anaerobic bacteria by oxidation processes. Because it is category C, it is less recommended for pregnant patients with rosacea and acne, compared with topical azelaic acid or erythromycin, which are recommended for these patients [18] .
Dapson is indicated as an adjuvant therapy for treatment of severe pemphigoid gestationis. Dapson is category C and should be considered only in severe refractory cases of pemphigoid gestationis during pregnancy. It is important to remember that patients with G6PD deficiency have a higher risk of developing severe dapson hypersensitivity reaction [51] .
Minoxidil is a topical treatment for androgenetic alopecia. Small studies report its safety during pregnancy, so it is listed as category C [52] .
Conclusions
It is clear that more research in needed on the effects of dermatologic medications on the pregnant woman and her fetus. While experimental studies on humans are out of the question, the data gleaned from the many case reports and reviews are helping to answer important life-and-death questions about drugs that physicians routinely prescribe for dermatology patients. Clinicians are urged to publish more articles on the safe use of drugs, as well as the harm unknowingly done by them. Only in this way can the medical community improve the safety of its practice and provide the best care to our patients without putting the pregnancy or the baby on board in jeopardy.
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